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Abstract Natalizumab is a widely accepted drug for the
relapsing–remitting subtype of multiple sclerosis (RRMS).
The present longitudinal exploratory study in RRMS
patients analyzes the effects of natalizumab treatment on
the levels of pro-inflammatory and anti-inflammatory
cytokine protein levels and also the frequency and
suppressor function of regulatory T cells. Flow cytometry
was used to determine cytokines and regulatory T cell
frequency while regulatory T cell suppressor function was
assayed in vitro at different time-points after starting with
natalizumab. Results showed serum levels of pro-
inflammatory interferon gamma and interleukin (IL)-
12p70, as well as anti-inflammatory IL-4 and IL-10, were
elevated just a few hours or days after first IV infusion of
natalizumab. Interestingly, other cytokines like IL-5 or IL-
13 were also elevated while pro-inflammatory IL-17, IL-2,
and IL-1β increased only after a long-term treatment,
suggesting different immune mechanisms. In contrast, we
did not observe any effect of natalizumab treatment on
regulatory T cell frequency or activity. In conclusion, these
results suggest natalizumab has other immunological effects
beyond VLA-4 interaction and inhibition of CNS extrava-
sation, the relevance of which is as yet unknown and
warrants further investigation.
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Introduction
Multiple sclerosis (MS) is a chronic autoimmune disease of
the central nervous system (CNS) in which the cytokines and
the inflammatory process are key factors. Cytokines like
interleukin (IL)-4, IL-2, or interferon gamma (IFN-γ) have
been widely studied in MS because of their immunomodula-
tory role. A critical step in the inflammatory process
underlying MS pathology is immune cell trafficking across
the blood–brain barrier, and this is associated with worsening
clinical symptoms. Natalizumab (Tysabri®, Biogen Idec,
CA), a monoclonal antibody designed against the α4 subunit
of α4β1 (very late antigen-4; VLA-4) and α4β7 receptors
located on the lymphocyte surface, has demonstrated
efficacy in reducing disease activity and relapse frequency
in MS patients and is widely accepted as a drug for the
relapsing–remitting subtype of multiple sclerosis (RRMS)[1–
3]. The humanized IgG4 specifically binds to the surface of
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mononuclear circulating blood cells presenting α4, thus
inhibiting the adhesion to the VCAM at the endothelium and
decreasing extravasation to adjacent tissues. In the context of
MS, which is usually considered a T cell autoimmune
disease affecting the CNS, the beneficial effects observed
with the treatment have been attributed to immunosuppres-
sion by a blockade on T cell trafficking through the
endothelium [4, 5].
The clinical improvement and efficacy observed in
natalizumab treatment are counter-weighted by important side
effects including opportunistic infections and also cases of
fatal progressive multifocal leukoencephalopathy (PML)
detected during the clinical trials [1]. Some questions still
remain unresolved as the effect of natalizumab in the first
days and months of treatment when allergic reactions and
acute infusion reactions can occur [6]. Antibody binding to
the VLA-4 receptor may not only play a role in inhibiting the
inflammation process but also have effects on the immune
system itself.
Although the mechanism of action of the drug is
supposed to be clear, the biological effects of integrin α4
blockade or T cell traffic inhibition are still unknown.
Already existing drugs for MS like interferon-beta or
glatiramer acetate seem to modify CD4+ CD25+ Foxp3
regulatory T cell activity [7–10] or promote the anti-
inflammatory cytokine pathway [11–14]. The goal of our
study was to gain insight into the immunological effects of
natalizumab treatment in RRMS patients over a period of
20 months with a focus on pro-inflammatory and anti-
inflammatory cytokine protein levels as well as regulatory
T cell frequency and suppressor function.
Patients and Methods
Patients
Twenty-two RRMS patients were recruited and followed in
an observational longitudinal cohort study over a period of
20 months after starting treatment with natalizumab
(standard—300 mg IV every 4 weeks). All patients fulfilled
the McDonald criteria for relapsing–remitting multiple
sclerosis [15]. Clinical follow-up consisted of neurological
visits with a rating on the expanded disability status scale
(EDSS) every 6 months. Blood samples were taken at 2 h;
4, 7, and 15 days; and 1 and 2 months, and one sample
from the 3–5-, 9–12-, and 15–20-month periods, always
before drug infusion; all samples were processed within 2 h
of extraction. All patients had been treated with immuno-
modulatory treatments (glatiramer acetate or β-interferon)
before starting with natalizumab (minimum wash-out
period of 1 month except 15 days for one patient). Patients
treated with immunosuppressive drugs or with cortico-
steroids for relapses less than 30 days before starting with
natalizumab were not included in this study. Control blood
samples were obtained from healthy donors recruited in our
facilities (six women and five men; age range, 25–30 years
old). The study was approved by the ethics committee of
our hospital, and all patients and controls included signed
an informed consent.
The mean age of RRMS patients was 35.53±8 years, and
women comprised the 75% (Table I). The median EDSS at
the beginning of the study was 3.69 and 3.73 after 1 year.
The annual relapse rate (ARR) was 2.5, and the disease
duration was 9.95±6 years. None of the patients received
immunomodulatory or immunosuppressive drug treatment
during the experiment, and one patient interrupted treatment
due to allergic side effects within the first 2 months. Clinical
laboratory parameters showed increased levels in the total
lymphocytes after 1 year. We obtained significantly higher
levels of IL-2, IL-8, and IFN-γ when comparing RRMS
patients at baseline with healthy controls (Table II), which
agrees with previous MS reports.
Clinical disease activity was evaluated with the EDSS
scale. Patients were classified in subgroups according to
EDSS values (0–3.5, 4–6.5) and the evidence of relapses
within the first year (yes or none). Laboratory parameters
were measured including LDH, transaminases, total lym-
phocytes, eosinophils and monocytes, and the total CD4
and CD8 counts.
Table I Patients’ characteristics at baseline and after treatment
Clinical laboratory data RRMS (n=22)
Mean age (years) 35.53±8
Sex (men/women) 5/17
Men disease duration (years) 9.95±6
EDSS (number of subjects)
0–3.5 8
4–6.5 14
Mean EDSS (initial/after 1 year) 3.69/3.73





Mean number of relapses
Previous year 1.73
First year with natalizumab 0.29
% of relapse reduction 83.1%
Median cell count [baseline/1st Year/2nd year]
Total lymphocytes (×103/μL) 1.91/2.64/3.43
Total monocytes (×103/μL) 0.51/0.49/0.52
CD4 (%) 39.0%/41.0%/41.0%
CD8 (%) 33.0%/26.0%/25.0%
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Cytokine Determination
All serum samples for cytokine determination were
obtained from 8 mL of fresh blood, centrifuged and stored
in 1.5 mL tubes, and frozen at −80°C until measured by
flow cytometry (CBA FlexSet—BD®Bioscience, Bedford,
MA, USA) following manufacturer’s instructions. Experi-
ments were carried out using a FACSCalibur Flow
Cytometer (BD Bioscience, USA). Cytokines analyzed
included in our analysis panel were (lower detection limits
are shown): IL-1α (1.0 pg/mL), IL-1β (2.3 pg/mL), IL-2
(11.2 pg/mL), IL-4 (1.4 pg/mL), IL-5 (1.1 pg/mL), IL-6
(1.6 pg/mL), IL-8 (1.2 pg/mL), IL-10 (0.13 pg/mL), IL-
12p70 (0.6 pg/mL), IL-13 (0.6 pg/mL), IL-17A (0.3 pg/mL),
MCP-1 (1.3 pg/mL), GM-CSF (0.2 pg/mL), tumor necrosis
factor (TNF; 0.7 pg/mL), and INF-γ (1.8 pg/mL). All
concentrations were transformed according to NIBSC/WHO
standards.
Regulatory T Cell Frequency and Activity
PBMCs were isolated from 18 mL of fresh blood samples
(stored in EDTA tubes) through Ficoll-Paque (GE-Health-
care, Amersham) density gradient centrifugation. Samples
were processed within 2 h of collection to avoid any
alterations. Regulatory T cells were isolated using a
commercial regulatory T cell isolation kit (Miltenyi Biotec,
Bergisch Gladbach, Germany) following the manufacturer’s
instructions. In order to analyze suppressor function, cells
were stimulated with anti-CD3 plus anti-CD28 (1 μg/mL)
in the presence or absence of previously purified regulatory
T cells as previously described [16]; 1×105 of T-
CD4+CD25high cells (activated regulatory T cells) were
co-cultured (or not) with 2×105 T-CD4+CD25low cells
(effector T cells). Purified T-CD4+CD25low cells cultured
alone were used as controls. After 7 days, cells were pulsed
during the last 6 h of culture with 1 μCi [3H]-thymidine
(PerkinElmer, Waltham, MA) and incorporation was mea-
sured in glass fiber filters (Filtermat A, Wallac, Oy Turku,
Finland) using a 1450 Microbeta luminescence counter
(PerkinElmer, Waltham, MA). Regulatory T cell markers
were determined by flow cytometry (FACSCalibur). We
used anti-CD4 and anti-CD25 (BD Bioscience) and also the
anti-FoxP3 staining kit (BD Bioscience) according to the
manufacturer’s instructions. Cells were stained with anti-
CTLA-4, anti-HLA-DR and anti-CD38 in order to measure
activation of regulatory T cell markers. Activated T cells
were defined as CD4+ CD38+ HLA-DR+ T cells as
previously described by the group of Sánchez-Ramón [16].
Stimulation and Proliferation Assay
A total of 105 isolated PBMCs purified from healthy
control samples were cultured in medium (GIBCO® RPMI
Media 1640—Invitrogen, CA, USA) in the presence of
growing concentrations of natalizumab (15, 25, and
125 μg/mL). Cytokine levels were determined in super-
natants obtained after 4 and 24 h using flow cytometry.
Cells were pulsed with 1 μCi [3H]-thymidine for 16 h in
order to determine proliferation levels.
Statistical Analysis
Due to asymmetrical distribution of the serum cytokine
levels, summary statistics are given as median and
interquartile range. After performing a non-parametric
Friedman test in order to analyze significant differences,
baseline cytokine levels were compared with levels at each
different time-point using the Wilcoxon signed rank test.
Patients were grouped depending on their EDSS (0–4, 4.5–
6.5) and evidence of relapses (yes or none) during
treatment. The same test was also used to compare the
levels of regulatory T cell markers as well as the suppressor
activity at the different time-points. In order to analyze
associations between the number of relapses and the levels
of specific cytokines, ranges were calculated for cytokine
values by comparing levels (in each patient) at baseline and
after 1 year. This allowed comparisons with the number of
relapses. Correlations were established by Spearman’s test.
Also, we tried to correlate result data with the number of
observed MRI lesions or the evidence (yes or none) of
adverse drug reactions. A simple Mann–Whitney U test
Cytokines RRMS Controls Cytokines RRMS Controls
IL-1α 4.53 (±2.23) 5.03 (±3.67) IL-12p70 4.11 (±1.25) 3.25 (±1.68)
IL-1β 2.44 (±0.5) 1.98 (±1.22) IL-13 2.75 (±1.05) 2.5 (±1.21)
IL-2 15.53 (±4.83)* 12.30 (±1.23)* IL-17 4.41 (±1.76) 4.22 (±1.35)
IL-4 3.50 (±1.28) 3.06 (±2.02) IFN-γ 4.58 (±2.3)* 2.51 (±1)*
IL-5 1.99 (±0.6) 2.2 (±0.9) TNF-α 6.55 (±2.56) 5.80 (±1.53)
IL-6 4.01 (±2.25) 5.86 (±3.02) GM-CSF 2.72 (±1.25) 4.5 (±3.10)
IL-8 26.31 (±11.56)* 11.54 (±4.12)* MCP-1 98.28 (±49.25) 74.25 (±39.25)
IL-10 3.26 (±1.4) 3.36 (±1.30)
Table II Levels of cytokines in
RRMS patients (baseline) com-
pared to controls
All concentrations are given in
picograms per milliliter. Means
and SD are shown
*p<0.05
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was used to compare cytokine levels between RRMS
patients at baseline with those in healthy donors. P<0.05
was considered as a significance threshold. Given the
exploratory nature of this study, no corrections for multiple
comparisons were made. Statistical analyses were per-
formed using GraphPad Prism 5.0 (San Diego, CA, USA).
Results
Cytokine Levels in Patients After Starting Treatment
Globally, patients treated with natalizumab presented higher
levels of both pro-inflammatory and anti-inflammatory
cytokines on follow-up. Anti-inflammatory interleukins IL-
4, IL-5, IL-10, and IL-13 were significantly augmented just a
few hours or days after the first administration (Fig. 1). In
counterpart, pro-inflammatory IFN-γ and IL-12p70 were
also significantly increased and remained elevated during the
first 2 months. Other cytokines included in our study tended
to rise (i.e., the IL-6 or IL-17), but no increase reached
significance. By the end of the first 2 months, all the
cytokines had returned to baseline (non-significant) levels.
Cytokine Levels in Long-Term Treatment
In long-term measurements, levels of specific cytokines were
also increased, but the overall response was more dissimilar.
Interestingly, while cytokines elevated in the initial stage
returned to basal levels, pro-inflammatory IL-17, IL-1β, and
IL-2 levels were increased (Fig. 2). Elevated levels were also
obtained for the anti-inflammatory cytokines IL-5 and IL-13
after 1 year of treatment.
Overall, we observed that cytokines were elevated at
different time-points and that they followed three different
patterns (Fig. 3). Some of the cytokines (group A) were
elevated only during the first month, just a few hours and days
after drug infusion. These included both pro-inflammatory
and anti-inflammatory cytokines (i.e., IL-4, IL-10, or IFN-γ).
In contrast, the typically pro-inflammatory cytokines IL-1β,
IL-2, and IL-17 (group B) were elevated only at the long-term
treatment. The last group, composed of anti-inflammatory
cytokines (IL-5 and IL-13), was elevated at both time-points
(group C), the beginning and at 1 year but not at the mid-term.
The levels of IL-1α, IL-6, IL-8, TNF-α, GM-CSF, and MCP-
1 seemed to be sustained at similar concentrations during
treatment and were not significantly elevated at any time-point
included in the study (data not shown).
Regulatory T Cell Frequency and Activity in Patients
Overall, the effect of natalizumab treatment on regulatory T
cells was not statistically significant. We did not find
differences in regulatory T cell frequency, although there
was a very slight decrease during the first month (Fig. 4a).
Levels of CD4+ CD25high Foxp3+ cells initially increased
but, after 4 days, were back to baseline levels. Looking at
the regulatory T cell activity, we also did not observe
differences compared to baseline suppressor function of
cells previously stimulated with anti-CD3 and anti-CD28
(Fig. 4b). In addition, there was no difference in CTLA4,
CD38, and HLA-DR activation marker levels in the CD4+
population.
Natalizumab Effects on PBMCS In Vitro
In vitro exposure to natalizumab does not affect prolifera-
tion or cytokine levels. Previous groups addressed this
question in CD4+ T cells alone [17]. However, the VLA-4
antigen is present in many blood cell subtypes, so we co-
cultured purified PBMCs in the presence of natalizumab.
We did not obtain significantly increased levels of
proliferation in cells cultured in the presence of the
antibody. Also, we did not obtain significantly different
levels of cytokines when natalizumab was present (data not
shown) in either 4- or 24-h cultures.
Discussion
This is the first study to show the effects of natalizumab
over a period of 20 months with a special focus on the first
hours, days, and months after initiating treatment. At the
protein level, we have detected that natalizumab therapy is
associated with an increase of pro-inflammatory and anti-
inflammatory cytokines within the first 2 months of
treatment. This affects IFN-γ and IL-12p70 and also the
anti-inflammatory IL-4 or IL-10. Interestingly, important
cytokines for MS such as IL-2, IL-17, or IL-1β were only
elevated after 1 year of treatment, suggesting different
immunologic mechanisms. It would be interesting to further
analyze whether the reduction to basal levels in the
cytokines after the first 2 months of treatment observed in
our study might be associated with the recently described
reduction in CD49d antigen expression and therefore a
possible reduction of antibody binding in circulating cells
[18]. A recent work has reported increased levels of T cells
secreting pro-inflammatory cytokines in blood circulation
in patients after 1 year of natalizumab treatment [17]. In
agreement with these results, we observed elevated serum
levels of pro-inflammatory IL-2, IL-17, and IL-1β after
1 year.
In our study of cytokines based on serum samples, we
have also taken into account the first hours and days after
the first administration of the antibody, when we were able
to detect differences in cytokine levels such as IFN-γ, IL-4,
626 J Clin Immunol (2011) 31:623–631
or IL-10. A recent paper studying cytokines in patients with
MS at baseline and after 1 year did not address some of the
cytokines included in our study such us IL-17, IL-12p70, or
IL-13 [19]. Our study has detected increased levels for IL-
1β, IL-2, and also IL17 in the long-term treatment. It would
be interesting to analyze in the future if the IL-23,
Fig. 1 Serum levels of cytokines in RRMSpatients after starting treatment
with Natalizumab. Increased levels were detected just few hours or days
after first dosing with IFN-γ, IL-12p70 as well as IL-4, IL-5, IL-10, and IL-
13, and remained elevated at different stages. By the end of the second
month, all the cytokine levels returned to basal levels. Concentrations are
given in picograms per milliliter. *p<0.05, **p<0.01, ***p<0.001
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Fig. 2 Long-term effects of natalizumab treatment in cytokine serum levels. Increased concentrations were detected for IL-1β, IL-2, and IL-17 and also
for IL-5 and IL-13. Serum levels are shown in picograms per milliliter. *p<0.05, **p<0.01, ***p<0.001
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implicated in Th17 cell induction, would also be increased
with natalizumab. Another recent paper has reported
increased levels of CD4+ T cells producing pro-
inflammatory IFN-γ, tumor necrosis factor (TNF), and
interleukin (IL)-17 upon stimulation in vitro with anti-CD3
in blood samples from patients after 6 months treatment
with natalizumab [20]. Those authors have also found that
the CD4+ markers CD25, HLA-DR, and CCR6, as well as
the frequency of CD8+ T cells producing IL-2 and IL-17,
were increased. In agreement with some of these observa-
tions, our results also suggest elevated IL-17 levels at the
long-term treatment with natalizumab. Although our obser-
vations require replication with larger numbers of patients
for confirmation, Natalizumab treatment did induce some
modifications in cytokine patterns in our cohort of RRMS
patients. Furthermore, these responses seemed to be
different at several stages; there was a rapid rise in
cytokines after the first administration when rejection and
allergic reaction might occur, whereas other cytokines were
only elevated at the long-term treatment when the risk of
opportunistic infections or PML risk is higher.
Natalizumab was not designed to have biological effects
upon binding to α4 but rather to physically interfere with
the endothelial attachment of VLA-4+ cells [1]. However,
previous studies in rats suggested that antibody binding to
VLA-4 might mediate VLA-4+ cell stimulation [21, 22]. As
we observed different cytokine response patterns in
patients, we decided to test whether natalizumab exposure
might affect mononuclear cells in vitro. Previous groups
have addressed this question for CD4+ T cells [17]. Since
the VLA-4 antigen is present in many blood cell subtypes,
we co-cultured total purified PBMCs in the presence of
physiological concentrations of natalizumab. We did not
detect significant effects on proliferation, and we did not
observe differences in cytokine patterns when the antibody
was present. Therefore, if natalizumab does have any effect
on blood cells, these effects might be more than just on
proliferation or cytokine production and should be further
addressed. It would be important to mention that this effect
(if it exists) might depend on the subject or patient studied
(note that we only used healthy donors because of the
heterogeneity of RRMS patients).
In accordance with recent studies, we found that natalizu-
mab does not affect regulatory T cell function. A recent study
showed that the capacity to migrate across the blood brain
barrier and suppressive function as well as foxp3+ cell
frequency seem to not be affected by natalizumab [18]. At
Fig. 4 Effects of natalizumab treatment on regulatory T cells.
Regulatory T cell frequency (a) is shown by following the regulatory
T cell markers CD25hi, Foxp3+, and CTLA4. None of the markers
changed significantly, although there was a non-significant relative
decrease in the first month. HLA-DR and CD38 activation markers
were also not affected by treatment (data not shown). In vitro
suppressor function of regulatory T cells is also shown (b). Peripheral
mononuclear cells were stimulated with anti-CD28 plus anti-CD3 in
the presence (or not) of purified regulatory T cells in order to obtain
percentages of proliferation under different conditions. Proliferation
levels of unstimulated cells were considered the control level for
suppression (100%)
Fig. 3 Longitudinal pattern of cytokine serum levels after treatment
with natalizumab. Three different patterns were observed after
initiating treatment with natalizumab in the patient cohort. Some of
the cytokines (Group A), including IL-4, IL-10, and IFN-γ, were
elevated only during the first month. In contrast, another group of pro-
inflammatory cytokines (Group B, including IL-1β, IL-2 and IL-17)
were elevated only at the long-term. The third group (Group C),
composed of the anti-inflammatory cytokines IL-5 and IL13, was
elevated only within the first month and at the end but normal in the
mid-term
J Clin Immunol (2011) 31:623–631 629
this time, there are contradictory results on the effect of
natalizumab on the frequency of circulating regulatory T
cells and another group has reported a relative decrease in
CD4+ CD25high cells [23]. However, none of these studies
have found any effect on the suppressor function of the cells
[18, 23]. In our case, we detected a relative tendency to a
decrease in the frequency of CD4+ CD25 FoxP3+ cells
within the first month (not significant); however, we also did
not obtain any difference in the suppressor function of these
cells in comparison with baseline levels. It would also be
interesting to consider other regulatory T cell markers in our
study like the ILR-7 receptor (CD127) or the CD39
ectonucleotidase [24], but, unfortunately, this was not
considered at the beginning of our study. Already existing
drugs for MS like interferon-beta and glatiramer acetate seem
to modify CD4+ CD25 + Foxp3 regulatory T cell activity [7–
10]. Regulatory T cells have been described as important
players in controlling immune response and balancing
tolerance versus autoimmune responses [25, 26]. Our results,
in accordance with some of the previous reports suggest that
natalizumab seems to exert its beneficial properties indepen-
dently of affecting regulatory T cell function.
In summary, treatment with natalizumab in RRMS
patients induces changes in the inflammatory mechanism.
While IFN-γ, IL-12p70, IL-4, and IL-10 were elevated just
a few hours or days after first IV infusion, pro-
inflammatory cytokines like IL-1β, IL-2, and IL-17 were
elevated only at the long-term treatment suggesting differ-
ent immune mechanisms. We have found that globally the
treatment with the antibody does not modify regulatory T
cell function. All these results suggest other immunological
effects of natalizumab in addition to VLA-4 interaction and
CNS extravasation inhibition. If these changes in the
cytokine equilibrium are related to beneficial or negative
side effects associated to natalizumab is as yet unknown
and requires further investigation.
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